INTRODUCTION
Interleukin 15 (IL-15) is a cytokine that has shown promising antitumor effects in preclinical studies (1) and clinical trials are currently ongoing (NCT01385423, NCT01369888, NCT01021059, NCT01572493). The main mechanisms of actions against cancer are based on eliciting or favouring proliferation and activation of both NK and memory CD8 T cells (2) . IL-15 is naturally expressed on the membrane of dendritic cells tethered to IL-15 receptor alpha (IL-15Rα). This cytokine-receptor complex triggers on cell-to-cell contacting lymphocytes the heterodimeric receptor formed by the subunits IL-2Rβ and the common γc (3). Activity on the IL-2Rβ/γc complex is a property shared by interleukin 2 (IL-2) and IL-15. In marked contrast to IL-2, IL-15 appears to be a better tool for cancer immunotherapy, since IL-15 does not promote activation-induced cell death and does not induce proliferation of T regulatory cells (4) .
One of the limitations of IL-15 to exert an efficacious antitumor effect is the short plasma half-life of the protein (5) . For this reason, various approaches to increase its stability have been undertaken. Gene therapy with viral vectors (6) , cells engineered to secrete IL-15 (7) and fusion proteins linking IL-15 to another larger protein fragment are among the possibilities to increase molecular weight and redirect the IL-15 to a specific target (8) . As mentioned, it has been shown that IL-15 naturally acts as a transpresented cytokine bound to the extracellular region of the IL-15Rα (to a domain called "sushi"). Complexes of IL-15 and the sushi domain of the IL-15Rα or fusion proteins containing both agents (9) have been used to strengthen its antitumor effect as a result of mimicking to some extent the naturally occurring trans-presentation mechanism (10).
Apolipoprotein A-I (Apo A-I) is the main protein component of the high-density lipoproteins (HDL) that circulate collecting cholesterol from tissues and bringing it to the liver (11) . Apo A-I is an amphiphilic protein, naturally synthesized in the liver and which has been already used to stabilize interferon α and target it to the liver (12) .
In a previous study, we constructed a plasmid coding for Apo A-I protein fused to hIL-15 (pApo-IL15) (Ochoa MC et al submitted). This expression plasmid was transferred to the liver by hydrodynamic injection, thereby obtaining a high and sustained concentration of the protein in serum and a clear effect on the proliferation of NK and CD8 T cells. When the liver transference was performed in combination with a separate plasmid coding for the sushi domain of IL-15Rα (pSushi), the effect on NK and T cell proliferation was enhanced and certain antitumor effects were attained albeit to a modest extent.
In the current study, we have designed and tested a triple fusion protein encompassing the sushi domain of the IL-15Rα, IL-15 and apolipoprotein A-I. 
IL-2Rγ
−/− and IL-15Rα -/-mice were obtained from The Jackson
Laboratory (Bar Harbor, ME, USA). GzmAxB -/-and perfxgzmAxB -/-mice (C57Bl/6 background) were kindly provided by Dr. Julian Pardo (University of Zaragoza, Spain).
They are homozygous triple knock out for granzymes A and B and perforin. They were originally created by crossing perf -/-with gzmAxB -/-mice (13) . These mice were maintained under pathogen-free conditions in the animal facilities of CITA (Agrifood Research and Technology Centre of Aragon) in Zaragoza, Spain. Mouse genotypes were periodically tested by PCR as previously described (13) . B16OVA melanomaderived cells were B16F10 cells transfected to express chicken OVA and have been described previously (14) . MC38 is a colon adenocarcinoma cell line of C57BL/6 origin (15). B16OVA and MC38 cell lines were validated by Idexx Radill © (Columbia, MO, USA) in 2012 (February) using a panel of microsatellite markers for genotyping.
Cell lines were maintained at 37°C in 5% CO 2 and were grown in RPMI medium (RPMI 1640) with Glutamax (Gibco, Invitrogen, Carlsbad, CA, USA) containing 10%
heat-inactivated FBS (Sigma-Aldrich, Dorset, UK), 100 IU/mL penicillin, 100 g/mL streptomycin (Biowhittaker, Walkersville, MD, USA) and 50 mmol/L 2-mercaptoethanol (Gibco). CTLL-2 is a stable subclone of cytotoxic T lymphocytes originally isolated from a C57BL/6 mouse and 200U/mL of IL-2 (Preprotech, Germany) was added in its culture medium (16) . PBMC were obtained from filters of blood donation units under informed consent following approval of the institutional ethical committee, CFSE stained and monitored as described (17) . Details on the isolation of mononuclear cells from spleen, lung and liver, as well as Antibodies, flow cytometry and immunoshistochemistry can be found as supplementary methods.
Plasmids
For sushi domain construction (pSushi), kindly provided by Dr. Bulfone-Paus, complete mIL-15Rα was cloned into the BamHI and NotI sites of the vector pcDNA™3.1 (Invitrogen, Carlsbad, CA, USA). The C-terminal part was removed by PCR (Uprim.
TAAAGAGGGCCCTATTCTATAGTG and Lprim. GGGGTCTCTGATGCACTT GAG) and subsequent ligation of the product.
Apolipoprotein A-I plasmid cloning (pApo) were designed using, the sense primer To fuse mSushi-mIL15 with ApoA-I, PCR amplification was carried out using the 
Hydrodynamic injections and ELISA
The plasmids were transferred by an intravenous injection (tail vein) of plasmid in a volume of 100ml/kg −1 using a 27-G needle at a rate of 0.4mls −1 , as previously described (18) .
In vivo tumor growth
For the intrasplenic tumor model, C57BL/6 mice received an injection of MC38 cells in mAb. When such mice received 10μg of pSushi-IL15-Apo, the construction was not lethal for those mice whose NK cells had been depleted with α-asialo GM1 ( figure 2B ).
In the group of Rag 1 -/-mice which received α-NK1.1 mAb, there was a residual lethality, but it was reduced to 60%. Our results do not offer evidence for clear superiority of pSushi-IL15-Apo over pSushi-IL15. Nonetheless, if mice are hydrodynamically injected with these expression constructs the 48h serum samples from these animals exerts proliferative bioactivity on CTLL2 cells when tested in multiple serial dilutions (supplementary figure 2D ). This suggests that the Sushi-IL15-Apo transgene is more bioactive in this treatment setting. and the metastases on the surface of this organ were counted. Mice that had received 1μg of pSushi-IL15-Apo were 100% metastasis-free in the liver ( figure 5A ). In addition, the spleens were examined and weighed to reflect the primary tumor size (figure 5B). 50% of mice from the group treated with pSushi-IL15-Apo did not present any macroscopic tumor in the spleen, whereas 100% of mice from the saline group had spleen tumors, 67% from the pApo group and 100% of the pApoIL15 + pSushi group.
Sushi-IL15-Apo recombinant protein administered i.v. is bioactive and elicits antitumor effects
Clinical feasibility of this treatment would benefit from using a recombinant protein as the therapeutic agent instead of performing cumbersome gene therapy procedures. The recombinant protein was produced in E. coli and purified by affinity chromatography.
SDS-PAGE and Ponceau staining were carried out to analyze the purity and integrity of the protein ( figure 6A ). In addition, the bioactivity of the protein was studied with a CTLL2 proliferation bioassay (figure 6B) and such bioactivity was also checked in terms of an assay to detect STAT-5 phosphorilation in primary lymphocytes. For the latter purpose, splenocytes were incubated overnight with recombinant IL-15 or rSushiApo-IL15 and then intracellular pSTAT-5 was studied by flow cytometry in T and NK cells. As can be seen in figure 6C , rSushi-IL15-Apo induced pSTAT-5 phosphorilation in NK and memory-phenotype CD8 T cells. Moreover, i.v. injection of rSushi-Apo-IL15 produced dose-dependent increases in the number of NK and memory CD8 T lymphocytes in the spleen, liver and lung (supplementary figure 5).
To ascertain if this fusion protein was active on human lymphocytes, CFSE-labelled PBMC from healthy volunteers were injected into the peritoneal cavity of Rag2 -/-IL- 
2Rγ
-/-mice. Such mice were iv treated with 50μg of recombinant Sushi-IL15-Apo or saline. As can be seen in figure 6D , gated human NK and CD8 T cells retrieved 6 days later from the peritoneum had proliferated in response to the injected fusion protein.
This is consistent with previous studies using IL-15 forms engineered to be transpresented (20) . giving an idea about the potency of the chimeric construction that we report.
We had previously studied Apo-IL15 non-covalently linked to IL-15Rα and it is clear that both biological effects and toxicity are much less pronounced. This is interpreted in the sense that covalent bounds enforce IL-15 trans-presentation by the IL-15Rα sushi domain (2) . Accordingly, this triple fusion cytokine represents a highly active form of IL-15. The Apo A-I, that forms part of the HDLs conceivably acts as a natural vehicle that facilitates the IL-15/IL-15Rα sushi domain anchorage for trans-presentation.
Another advantage of Apo A-I is that this protein has been reported to exert some not well understood antitumor properties (23) .
For clinical translation, our observations on acute toxicity might look worrisome.
However, it must be taken into account that because of using gene therapy, we are clearly overdosing the cytokine. In a sense, finding a maximal tolerated dose suggests that our construct is making the most of the IL-15 system. This is important for translation since IL-15 enjoys the reputation of a great potential in immunotherapy (24) with a very safe preclinical profile.
The activity observed with the recombinant protein is a step forward towards clinical translation. In the case of this construct, exogenous administration of protein at reliably controlled levels is probably safer. The only advantage of the gene therapy approach used for the proof-of-concept experimentation is that the liver is the natural bioreactor of HDLs in the organism. Indeed, the approach with recombinant proteins is the most feasible for translation. Other groups have used linked forms of IL-15Rα to IL-15 (9) with biological effects on lymphocytes as well as with therapeutic effects on transplanted tumors (10) . It is early to decide without comparative studies which of these fusion proteins will offer the best and safest pharmacokinetics and pharmacodynamics but incorporation into lipoproteins may have advantages.
The effectiveness of therapy is particularly remarkable against B16OVA-derived metastasis even when given 4 days after tumor cell inoculation. This observation on efficacy against lung tumors could be related to the propensity of NK cells and CD8 T lymphocytes to infiltrate the lung under these therapeutic conditions. In this regard, toxicity is considered an on-target side effect for which a therapeutic window was found. Human malignancies progress more slowly than mouse transplanted tumors. Therefore, we tested if doses can be repeated to weeks apart in mice, and we found that the increases in NK and CD8 memory T cells were comparable or even higher 4 days after the second hydrodynamic treatment. Accordingly, repeated doses seem to be feasible without desensitization or cumulative toxicity (supplementary figure 6) .
Apo A-I-linked cytokines may add interesting immunotherapeutic properties (12) . In this case, Sushi-IL15-Apo holds promise for metastatic disease and deserves clinical development. We eagerly expecting results for the first in human trials of IL-15 as a single agent (NCT01385423, NCT01369888, NCT01021059, NCT01572493) following its excellent safety profile in non-human primates (25) . Nonetheless more bioactive and stable forms of IL-15 should follow in clinical development to make the most of this therapeutic tool. 
